All News

hands pregnant

Improved Pregnancy Outcomes in SLE (2010–2020)

d Jack Cush, MD

A retrospective cohort study has shown that outcomes in pregnant systemic lupus erythematosus (SLE) patients has significantly improved in the last decade, but there still is a high risk of adverse pregnancy outcomes (APO).

Read Article
healthcare.costs_.jpg

ACR Applauds FTC Decision to Investigate PBM's

d ACR Press Release

The American College of Rheumatology applauds the Federal Trade Commission’s decision to investigate the business practices of pharmacy benefit managers (PBMs), which continue to increase PBM profit margins while placing the burden of skyrocketing drug costs on America’s most vulnerable patients,

Read Article
Smile feedback opinion yes no good back opinion

What do our lupus patients think about treat-to-target?

d Md Yuzaiful Md Yusof, MRCP(UK), PhD

In SLE, two targets that are increasingly used are the DORIS 2021 Remission and the Lupus Low Disease Activity (LLDAS). T2T is more likely to be successful if the treating clinicians and the patients set the treatment goals together. What do our patients think about T2T and do they have any say/concern?

Read Article
450 axSpA pts followed 2868 Pt-yrs, 48% on TNFis. TNFi Rx pts had reduced CV risk (HR 0.30; 0.10–0.85), but no longer signif after adjustment for CRP, ESR (HR 0.37, 0.12–1.12, p = 0.077). Reduced CV risk, may not be specifically due to TNFi use https://t.co/mVHYn3PteL https://t.co/bgKWreBL8z

Links:

Dr. John Cush RheumNow ( View Tweet)
JAKi not yet safe in pregnancy - theyre fetotoxic at high doses (animals). JAKi do cross placenta. ACR Guidelines: no position due to no data. 47 tofa Rheum & 15 UC maternal exposures - no signif probs. Paternal use of JAKi is ok. https://t.co/pom5KD0qt7 https://t.co/djYHZ5LdcE https://t.co/47lfyZC4H3

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: The Microbiome in Spondyloarthritis Can microbes trigger SpA/PsA? https://t.co/KN7dMFU9qo https://t.co/k3M5QfwqGp

Links:

Dr. John Cush RheumNow ( View Tweet)
Cluster study of 383 aPL+ pts showed 4 clusters: Cluster 1 (138): w/ SLE & non-criteria Sxs Cluster 2 (112): pts w/ CV risks Cluster 3 (83): females w/ OB morbidity (BEST outcome) Cluster 4 (50): lupus anticoagulant (+) (high freq of arterial thrombosis) https://t.co/HGRTceplsn https://t.co/ZDdwhCmj5r

Links:

Dr. John Cush RheumNow ( View Tweet)
GLORIA Study Pred vs PBO in >65yrs RA x 2 years. 451 Pts & DAS28 4.5. 79% on DMARDs (14% biologics) Upside: Lower DAS28 -0.37 & less Xray progression -1.7 Sharp units Downside: 24% more AE (mild infxns), signif.small lowering of lumbar BMD -1% You Decide https://t.co/RRq0WcFsXz https://t.co/xLxjPPSMhh

Links:

Dr. John Cush RheumNow ( View Tweet)
MMWR: Monkeypox Outbreak in Nine States CDC is tracking multiple reported U.S. monkeypox cases, and monitoring cases in persons in countries without endemic monkeypox and with no known travel links to an endemic area. https://t.co/Pr0n7pwAgS https://t.co/DvJtLq85E2

Links:

Dr. John Cush RheumNow ( View Tweet)
CV risk factors not equal when considering magnitude of risk What can we learn from Oral Surveillance? The Oral Surveillance trial has almost become a household word for rheumatologists. https://t.co/LHZTVZh4AK https://t.co/2SlxrG7UpQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: #EULAR2022 - Day 4 Faculty Panel Recap Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006. https://t.co/HomsEG9CdX https://t.co/LdMa2FUe76

Links:

Dr. John Cush RheumNow ( View Tweet)
WATCH: #EULAR2022 - Day 3 Faculty Panel Recap Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022. https://t.co/6Xdu3acGXN @Janetbirdope @AurelieRheumo @Yuz6Yusof https://t.co/juFkMtF5hS

Links:

Dr. John Cush RheumNow ( View Tweet)
#EULAR2022 - Day 2 Faculty Recap Panel Dr. Jack Cush, Dr. Robert Chao and Dr. Richard Conway discuss interesting abstracts and seminars from day 2 at EULAR 2022. https://t.co/aTVKYhggGD @doctorRBC @RichardPAConway https://t.co/kn3PkaFGSy

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: EULAR 2022 - Day 1 Faculty Recap Pane Drs. Jack Cush, Eric Dein and Kathryn Dao discuss highlights from day 1 at #EULAR2022 - Guidelines, Lupus, and more. https://t.co/WSOCQ8K38p https://t.co/0u28QHtxoJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Getting Real on PMR Dr. David Liew talks polymyalgia rheumatica and how our understanding has evolved over the years. #EULAR2022 https://t.co/j4LJPZFqzY https://t.co/ABAbm3axSG

Links:

Dr. John Cush RheumNow ( View Tweet)
Polymyalgia rheumatica immunological puzzle further illustrated Infiltrating macrophages expressing IL-6 and GM-CSF may drive the subacromial bursitis often seen in polymyalgia rheumatica, according to new research presented at #EULAR2022. https://t.co/Miab1eiHZ6 https://t.co/n9IjPwqG2t

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch this 4 minute video on Belimumab use in pregnancy featuring Dr. Kathryn Dao ( @KDAO2011 ) https://t.co/8uRUIVURHF https://t.co/lbYwHFFJit

Links:

Dr. John Cush RheumNow ( View Tweet)
Studies suggest that the IL-23/Th-17 axis is one of the key pathways involved in the pathogenesis of plaque psoriasis and psoriatic arthritis. Learn more here: https://t.co/oj00pk4dLT Sponsored by Janssen @JanssenUS https://t.co/4IhyX6sF7p

Links:

Dr. John Cush RheumNow ( View Tweet)
Miss this week's TNR? Watch the playback. https://t.co/LSlw939Vj2 https://t.co/K62afKWz95

Links:

Dr. John Cush RheumNow ( View Tweet)
Can we stop RA before it happens? Rheumatologists have long hoped and wondered whether the right type of early intervention could prevent RA occurring in at-risk individuals. https://t.co/vU4tRr7UJh https://t.co/cikU9pwaiT

Links:

Dr. John Cush RheumNow ( View Tweet)
×